Last reviewed · How we verify
Fluzone-High Dose Quadrivalent
At a glance
| Generic name | Fluzone-High Dose Quadrivalent |
|---|---|
| Also known as | High-dose flu vaccine |
| Sponsor | Vanderbilt University Medical Center |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Influenza Vaccination Strategy for Patients With Hematologic Malignancy (PHASE3)
- A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults (PHASE1)
- A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza (PHASE1)
- A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast Cancer (PHASE1)
- Clinical Trial of Quadrivalent Subunit Influenza Vaccine (Adjuvant) in Chinese Population Aged 65 Years and Older (PHASE1)
- High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients (PHASE2)
- A Study on the Safety and Immunogenicity of Influenza, Respiratory Syncytial Virus, Human Metapneumovirus and Parainfluenza Vaccines in Adults 18 to 49 Years of Age. (PHASE1)
- Study on a High-Dose Quadrivalent Influenza Vaccine Compared With Standard-Dose Quadrivalent Influenza Vaccine in Children 6 Months Through 35 Months of Age (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fluzone-High Dose Quadrivalent CI brief — competitive landscape report
- Fluzone-High Dose Quadrivalent updates RSS · CI watch RSS
- Vanderbilt University Medical Center portfolio CI